Running Point Capital Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

Running Point Capital Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-667	Closed	-$34K	–	179
2022 Q4	$34K	Hold	667	–	–	0.02%	170
2022 Q3	$55K	Hold	667	–	–	0.04%	154
2022 Q2	$45K	Hold	667	–	–	0.03%	160
2022 Q1	$74K	Buy	+667	New	+$83.1K	0.04%	149

Other funds holding KPTI

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Running Point Capital Advisors's KPTI Position: Q1 2023 in Review

Running Point Capital Advisors sold out of Karyopharm Therapeutics (KPTI) in Q1 2023, closing a stake of 667 shares — an estimated $34K sold.

Running Point Capital Advisors first reported a position in KPTI in Q1 2022 and held it in 4 quarters. The position peaked at $74K in Q1 2022. 129 funds tracked by Wall St. Rank hold KPTI as of Q1 2023.

Running Point Capital Advisors reported no remaining Karyopharm Therapeutics position as of Q1 2023 after selling out during the quarter.
Running Point Capital Advisors sold 667 Karyopharm Therapeutics shares in Q1 2023, an estimated $34K.
Running Point Capital Advisors first reported a position in Karyopharm Therapeutics in Q1 2022 and held it in 4 quarters.
Running Point Capital Advisors's Karyopharm Therapeutics position peaked at $74K in Q1 2022.
129 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2023.

Based on Running Point Capital Advisors's 13F filing for Q1 2023, filed 10 May 2023.